Integrin Alpha V Beta 3-targeting Protein ACT50

**Semantic type:** Pharmacologic Substance

**Definition:** An integrin alpha V beta 3-targeting protein, with potential pro-apoptotic, anti-angiogenic and antineoplastic activities. Upon administration, integrin alpha V beta 3-targeting protein ACT50 targets the cell surface receptor integrin alpha V beta 3, at a site other than the ligand-binding site, expressed on angiogenic endothelial cells (aECs) and cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME), and recruits and activates caspase 8. This leads to the apoptosis of alpha V beta 3-expressing aECs and CAFs, and may inhibit tumor growth, angiogenesis, and metastasis. Alpha V beta 3 integrin, a cell adhesion and signaling receptor, is expressed on the surface of aECs, CAFs and some tumor cells and has been associated with increased proliferation, migration and invasion of tumor cells.

**Synonyms:** - ACT 50 - ACT-50 - ACT50 - ProAgio